Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

FRANCIS J AVERILL

Allopathic & Osteopathic Physicians Internal Medicine Pulmonary Disease

NPI
1629005020
CMS profile
299971
Location
CLEARWATER, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$94,821.12

232 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

Page 2 of 5; records 51–100 of 232 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

FRANCIS J AVERILL

NPI 1629005020 · CMS profile ID 299971

Allopathic & Osteopathic Physicians / Internal Medicine / Pulmonary Disease

CLEARWATER, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 5; records 51–100 of 232 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1629005020?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
FRANCIS J AVERILL, NPI 1629005020, CMS profile ID 299971. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 5; records 51–100 of 232 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1629005020?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). FRANCIS J AVERILL, NPI 1629005020, CMS profile ID 299971. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 5; records 51–100 of 232 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1629005020?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
FRANCIS J AVERILL, NPI 1629005020, CMS profile ID 299971, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 5; records 51–100 of 232 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1629005020?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

232 matching records · $94,821.12 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 232 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 232.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
JAZZ PHARMACEUTICALS INC. $18.4010/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150223646 CMS
Electromed, Inc. $17.6510/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137878411 CMS
3B Medical, Inc. $13.0910/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147571969 CMS
Insmed, Inc. $8.2910/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089572052 CMS
AstraZeneca Pharmaceuticals LP $75.6910/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110531379 CMS
AstraZeneca Pharmaceuticals LP $27.9510/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110535464 CMS
AstraZeneca Pharmaceuticals LP $30.0010/24/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110540471 CMS
AstraZeneca Pharmaceuticals LP $2,128.2410/24/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110550230 CMS
AstraZeneca Pharmaceuticals LP $74.0010/24/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110552510 CMS
AstraZeneca Pharmaceuticals LP $666.2110/24/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110553280 CMS
Merck Sharp & Dohme LLC $28.2310/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141633923 CMS
GlaxoSmithKline, LLC. $21.2010/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116680591 CMS
Paratek Pharmaceuticals, Inc. $20.4010/21/2024 Food and Beverage No dispute reported Delay: No
Change: CHANGED
06/30/2026 1113891638 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $21.2510/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118084288 CMS
AstraZeneca Pharmaceuticals LP $3,700.0010/15/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110536902 CMS
AstraZeneca Pharmaceuticals LP $3,700.0010/10/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110548302 CMS
AstraZeneca Pharmaceuticals LP $1,400.0010/02/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110544755 CMS
AstraZeneca Pharmaceuticals LP $1,387.2310/01/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110543955 CMS
AstraZeneca Pharmaceuticals LP $838.6810/01/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110547406 CMS
AstraZeneca Pharmaceuticals LP $103.4610/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110551552 CMS
AstraZeneca Pharmaceuticals LP $14.8209/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110540287 CMS
AstraZeneca Pharmaceuticals LP $3,700.0009/26/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110543953 CMS
AstraZeneca Pharmaceuticals LP $15.9409/25/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110548974 CMS
Insmed, Inc. $6.1209/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089557388 CMS
JAZZ PHARMACEUTICALS INC. $27.1309/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150223656 CMS
Harmony Biosciences Llc $21.2309/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141477914 CMS
AstraZeneca Pharmaceuticals LP $2,800.0009/20/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110551970 CMS
Regeneron Healthcare Solutions, Inc. $30.6109/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114002374 CMS
AstraZeneca Pharmaceuticals LP $80.7709/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110544697 CMS
AstraZeneca Pharmaceuticals LP $803.6109/16/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110554190 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $24.2909/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118084290 CMS
Amgen Inc. $19.3509/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111520879 CMS
AstraZeneca Pharmaceuticals LP $17.9309/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110555070 CMS
AstraZeneca Pharmaceuticals LP $18.7809/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110552916 CMS
Insmed, Inc. $18.0609/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089557352 CMS
GlaxoSmithKline, LLC. $29.9709/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1115824862 CMS
Mallinckrodt Hospital Products Inc. $38.7008/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145047793 CMS
AstraZeneca Pharmaceuticals LP $3,750.0008/29/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110542997 CMS
HARMONY BIOSCIENCES LLC $22.3908/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1126061430 CMS
AstraZeneca Pharmaceuticals LP $15.4508/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110551554 CMS
JAZZ PHARMACEUTICALS INC. $26.0208/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150223660 CMS
JAZZ PHARMACEUTICALS INC. $99.0008/27/2024 Education No dispute reported Delay: No
Change: NEW
06/30/2026 1155980455 CMS
Regeneron Healthcare Solutions, Inc. $86.6608/27/2024 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114002372 CMS
Amgen Inc. $18.9208/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111520877 CMS
GlaxoSmithKline, LLC. $21.2008/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116484505 CMS
United Therapeutics Corporation $23.7808/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1149470532 CMS
3B Medical, Inc. $20.2908/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147571965 CMS
AstraZeneca Pharmaceuticals LP $17.7808/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110539891 CMS
Insmed, Inc. $23.2508/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089557918 CMS
Grifols USA, LLC $24.7208/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1124747065 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $8,955.06 189
PY2020 $17,013.56 154
PY2021 $46,002.38 192
PY2022 $48,582.01 213
PY2023 $50,267.26 198
PY2024 $94,821.12 232
PY2025 $101,646.31 242

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,079,226.22 361
PY2024 Principal investigator $1,630,664.43 339
PY2023 Recipient $37,250.49 8
PY2023 Principal investigator $961,208.18 218
PY2022 Principal investigator $433,875.64 120
PY2021 Recipient $74.51 1
PY2021 Principal investigator $669,758.16 155
PY2020 Recipient $34.82 1
PY2020 Principal investigator $485,724.55 143
PY2019 Recipient $15,237.70 9
PY2019 Principal investigator $623,053.67 58

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

361 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 GlaxoSmithKline, LLC. $693.80 12/24/2025 Non-covered Recipient Entity
ST FRANCIS HOLDINGS LLC
A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF No dispute reported 06/30/2026 1192165365
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,271.81 12/24/2025 Non-covered Recipient Entity
ST FRANCIS MEDICAL INSTITUTE
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184280234
Principal investigator 1 United Therapeutics Corporation $1,704.30 12/24/2025 Non-covered Recipient Entity
St Francis Holdings LLC
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242388303
Principal investigator 1 Insmed, Inc. $150.00 12/19/2025 Non-covered Recipient Entity
St. Francis Medical Institute - Clinedge - PPDS
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646646
Principal investigator 1 Insmed, Inc. $150.00 12/19/2025 Non-covered Recipient Entity
St. Francis Medical Institute - Clinedge - PPDS
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646648
Principal investigator 1 Insmed, Inc. $150.00 12/19/2025 Non-covered Recipient Entity
St. Francis Medical Institute - Clinedge - PPDS
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646650
Principal investigator 1 Insmed, Inc. $150.00 12/19/2025 Non-covered Recipient Entity
St. Francis Medical Institute - Clinedge - PPDS
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646652
Principal investigator 1 Insmed, Inc. $150.00 12/19/2025 Non-covered Recipient Entity
St. Francis Medical Institute - Clinedge - PPDS
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646654
Principal investigator 1 Insmed, Inc. $150.00 12/19/2025 Non-covered Recipient Entity
St. Francis Medical Institute - Clinedge - PPDS
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646656
Principal investigator 1 Insmed, Inc. $150.00 12/19/2025 Non-covered Recipient Entity
St. Francis Medical Institute - Clinedge - PPDS
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646658
Principal investigator 1 Insmed, Inc. $250.00 12/19/2025 Non-covered Recipient Entity
St. Francis Medical Institute - Clinedge - PPDS
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646660
Principal investigator 1 Insmed, Inc. $250.00 12/19/2025 Non-covered Recipient Entity
St. Francis Medical Institute - Clinedge - PPDS
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646662
Principal investigator 1 Insmed, Inc. $250.00 12/19/2025 Non-covered Recipient Entity
St. Francis Medical Institute - Clinedge - PPDS
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646664
Principal investigator 1 Insmed, Inc. $630.00 12/19/2025 Non-covered Recipient Entity
St. Francis Medical Institute - Clinedge - PPDS
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646668
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $28.00 12/17/2025 Non-covered Recipient Entity
St Francis Holdings LLC St Francis Medical Institute
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220799606
Principal investigator 1 Genentech, Inc. $1,300.00 12/17/2025 Non-covered Recipient Entity
ST FRANCIS SLEEP ALLERGY AND
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211658976
Principal investigator 1 Genentech, Inc. $135.00 12/17/2025 Non-covered Recipient Entity
ST FRANCIS SLEEP ALLERGY AND
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211658980
Principal investigator 1 Genentech, Inc. $135.00 12/17/2025 Non-covered Recipient Entity
ST FRANCIS SLEEP ALLERGY AND
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211658983
Principal investigator 1 Genentech, Inc. $135.00 12/17/2025 Non-covered Recipient Entity
ST FRANCIS SLEEP ALLERGY AND
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211658987
Principal investigator 1 Genentech, Inc. $900.00 12/17/2025 Non-covered Recipient Entity
ST FRANCIS SLEEP ALLERGY AND
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211658991
Principal investigator 1 Genentech, Inc. $135.00 12/17/2025 Non-covered Recipient Entity
ST FRANCIS SLEEP ALLERGY AND
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211658995
Principal investigator 1 Genentech, Inc. $250.00 12/17/2025 Non-covered Recipient Entity
ST FRANCIS SLEEP ALLERGY AND
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211658999
Principal investigator 1 Genentech, Inc. $250.00 12/17/2025 Non-covered Recipient Entity
ST FRANCIS SLEEP ALLERGY AND
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211659003
Principal investigator 1 Genentech, Inc. $135.00 12/17/2025 Non-covered Recipient Entity
ST FRANCIS SLEEP ALLERGY AND
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211659007
Principal investigator 1 Genentech, Inc. $135.00 12/17/2025 Non-covered Recipient Entity
ST FRANCIS SLEEP ALLERGY AND
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211659011
Principal investigator 1 Genentech, Inc. $405.00 12/17/2025 Non-covered Recipient Entity
ST FRANCIS SLEEP ALLERGY AND
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211659016
Principal investigator 1 Genentech, Inc. $900.00 12/17/2025 Non-covered Recipient Entity
ST FRANCIS SLEEP ALLERGY AND
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211659019
Principal investigator 1 Genentech, Inc. $250.00 12/17/2025 Non-covered Recipient Entity
ST FRANCIS SLEEP ALLERGY AND
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211659026
Principal investigator 1 Genentech, Inc. $270.00 12/17/2025 Non-covered Recipient Entity
ST FRANCIS SLEEP ALLERGY AND
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211659030
Principal investigator 1 Genentech, Inc. $135.00 12/17/2025 Non-covered Recipient Entity
ST FRANCIS SLEEP ALLERGY AND
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211659034
Principal investigator 1 Genentech, Inc. $1,500.00 12/17/2025 Non-covered Recipient Entity
ST FRANCIS SLEEP ALLERGY AND
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211659037
Principal investigator 1 Genentech, Inc. $135.00 12/17/2025 Non-covered Recipient Entity
ST FRANCIS SLEEP ALLERGY AND
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211659042
Principal investigator 1 Genentech, Inc. $250.00 12/17/2025 Non-covered Recipient Entity
ST FRANCIS SLEEP ALLERGY AND
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211659046
Principal investigator 1 Genentech, Inc. $250.00 12/17/2025 Non-covered Recipient Entity
ST FRANCIS SLEEP ALLERGY AND
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211659051
Principal investigator 1 Genentech, Inc. $1,500.00 12/17/2025 Non-covered Recipient Entity
ST FRANCIS SLEEP ALLERGY AND
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211659054
Principal investigator 1 Genentech, Inc. $270.00 12/17/2025 Non-covered Recipient Entity
ST FRANCIS SLEEP ALLERGY AND
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211659059
Principal investigator 1 Genentech, Inc. $1,000.00 12/17/2025 Non-covered Recipient Entity
ST FRANCIS SLEEP ALLERGY AND
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211659062
Principal investigator 1 Genentech, Inc. $250.00 12/17/2025 Non-covered Recipient Entity
ST FRANCIS SLEEP ALLERGY AND
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211659068
Principal investigator 1 Insmed, Inc. $2,000.00 12/17/2025 Non-covered Recipient Entity
St. Francis Medical Institute - Clinedge - PPDS
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646666
Principal investigator 1 Insmed, Inc. $500.00 12/17/2025 Non-covered Recipient Entity
St. Francis Medical Institute - Clinedge - PPDS
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646670
Principal investigator 1 Insmed, Inc. $1,400.00 12/17/2025 Non-covered Recipient Entity
St. Francis Medical Institute - Clinedge - PPDS
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646672
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $27.60 12/15/2025 Non-covered Recipient Entity
St Francis Holdings LLC St Francis Medical Institute
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) No dispute reported 06/30/2026 1220799624
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $27.60 12/15/2025 Non-covered Recipient Entity
St Francis Holdings LLC St Francis Medical Institute
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) No dispute reported 06/30/2026 1220799626
Principal investigator 1 Genentech, Inc. $7,032.00 12/11/2025 Non-covered Recipient Entity
ST FRANCIS SLEEP ALLERGY AND LUNG INSTITUTE
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211659168
Principal investigator 1 Genentech, Inc. $34,126.00 12/11/2025 Non-covered Recipient Entity
ST FRANCIS SLEEP ALLERGY AND LUNG INSTITUTE
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211659173
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $28.00 12/10/2025 Non-covered Recipient Entity
St Francis Holdings LLC St Francis Medical Institute
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220799600
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $28.00 12/10/2025 Non-covered Recipient Entity
St Francis Holdings LLC St Francis Medical Institute
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220799602
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $28.00 12/10/2025 Non-covered Recipient Entity
St Francis Holdings LLC St Francis Medical Institute
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220799604
Principal investigator 1 Mannkind Corporation $2,500.00 12/10/2025 Non-covered Recipient Entity
ST FRANCIS MEDICAL INSTITUTE
ICON-1 PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF TREATMENT WITH MNKD-101, CLOFAZAMINE INHALATION SUSPENSION No dispute reported 06/30/2026 1250898672
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,956.20 12/03/2025 Non-covered Recipient Entity
St Francis Holdings LLC St Francis Medical Institute
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) No dispute reported 06/30/2026 1220799622
Principal investigator 1 Boehringer Ingelheim International GmbH $34.63 12/01/2025 Non-covered Recipient Entity
ST FRANCIS MEDCL INST
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220622762
Principal investigator 1 Boehringer Ingelheim International GmbH $3.86 12/01/2025 Non-covered Recipient Entity
ST FRANCIS MEDCL INST
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220622764
Principal investigator 1 Boehringer Ingelheim International GmbH $34.63 12/01/2025 Non-covered Recipient Entity
ST FRANCIS MEDCL INST
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220622766
Principal investigator 1 Boehringer Ingelheim International GmbH $3.86 12/01/2025 Non-covered Recipient Entity
ST FRANCIS MEDCL INST
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220622768
Principal investigator 1 Boehringer Ingelheim International GmbH $7.08 12/01/2025 Non-covered Recipient Entity
St Francis Sleep Allergy And Lung Institute LLC
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220724779
Principal investigator 1 Boehringer Ingelheim International GmbH $11.29 12/01/2025 Non-covered Recipient Entity
St Francis Sleep Allergy And Lung Institute LLC
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220724781
Principal investigator 1 Boehringer Ingelheim International GmbH $94.42 12/01/2025 Non-covered Recipient Entity
St Francis Sleep Allergy And Lung Institute LLC
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220724783
Principal investigator 1 Boehringer Ingelheim International GmbH $15.39 12/01/2025 Non-covered Recipient Entity
St Francis Sleep Allergy And Lung Institute LLC
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220724785
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $232.00 12/01/2025 Non-covered Recipient Entity
ST FRANCIS MEDCL INST
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220791671
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $34.00 12/01/2025 Non-covered Recipient Entity
ST FRANCIS MEDCL INST
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220791673
Principal investigator 1 United Therapeutics Corporation $331.20 11/26/2025 Non-covered Recipient Entity
St Francis Holdings LLC
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242388293
Principal investigator 1 United Therapeutics Corporation $1,524.90 11/26/2025 Non-covered Recipient Entity
St Francis Holdings LLC
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242388301
Principal investigator 1 GlaxoSmithKline, LLC. $2,288.00 11/24/2025 Non-covered Recipient Entity
ST FRANCIS HOLDINGS LLC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192163802
Principal investigator 1 GlaxoSmithKline, LLC. $11,676.00 11/24/2025 Non-covered Recipient Entity
ST FRANCIS HOLDINGS LLC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192163806
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,247.28 11/19/2025 Non-covered Recipient Entity
ST FRANCIS MEDICAL INSTITUTE
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184262495
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $198.72 11/19/2025 Non-covered Recipient Entity
ST FRANCIS MEDICAL INSTITUTE
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184262497
Principal investigator 1 United Therapeutics Corporation $5,023.20 11/12/2025 Non-covered Recipient Entity
St Francis Holdings LLC
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242388311
Principal investigator 1 Boehringer Ingelheim International GmbH $34.63 11/01/2025 Non-covered Recipient Entity
ST FRANCIS MEDCL INST
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220622754
Principal investigator 1 Boehringer Ingelheim International GmbH $3.86 11/01/2025 Non-covered Recipient Entity
ST FRANCIS MEDCL INST
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220622756
Principal investigator 1 Boehringer Ingelheim International GmbH $34.63 11/01/2025 Non-covered Recipient Entity
ST FRANCIS MEDCL INST
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220622758
Principal investigator 1 Boehringer Ingelheim International GmbH $3.86 11/01/2025 Non-covered Recipient Entity
ST FRANCIS MEDCL INST
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220622760
Principal investigator 1 Boehringer Ingelheim International GmbH $7.08 11/01/2025 Non-covered Recipient Entity
St Francis Sleep Allergy And Lung Institute LLC
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220724771
Principal investigator 1 Boehringer Ingelheim International GmbH $11.29 11/01/2025 Non-covered Recipient Entity
St Francis Sleep Allergy And Lung Institute LLC
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220724773
Principal investigator 1 Boehringer Ingelheim International GmbH $94.42 11/01/2025 Non-covered Recipient Entity
St Francis Sleep Allergy And Lung Institute LLC
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220724775
Principal investigator 1 Boehringer Ingelheim International GmbH $15.39 11/01/2025 Non-covered Recipient Entity
St Francis Sleep Allergy And Lung Institute LLC
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220724777
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $232.00 11/01/2025 Non-covered Recipient Entity
ST FRANCIS MEDCL INST
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220791667
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $34.00 11/01/2025 Non-covered Recipient Entity
ST FRANCIS MEDCL INST
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220791669
Principal investigator 1 Boehringer Ingelheim International GmbH $36.50 10/27/2025 Non-covered Recipient Entity
ST FRANCIS MEDCL INST
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220622770
Principal investigator 1 Boehringer Ingelheim International GmbH $11.66 10/27/2025 Non-covered Recipient Entity
St Francis Sleep Allergy And Lung Institute LLC
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220724787
Principal investigator 1 Boehringer Ingelheim International GmbH $73.00 10/27/2025 Non-covered Recipient Entity
St Francis Sleep Allergy And Lung Institute LLC
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220724789
Principal investigator 1 Boehringer Ingelheim International GmbH $4.64 10/27/2025 Non-covered Recipient Entity
St Francis Sleep Allergy And Lung Institute LLC
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220724791
Principal investigator 1 Boehringer Ingelheim International GmbH $10.00 10/27/2025 Non-covered Recipient Entity
St Francis Sleep Allergy And Lung Institute LLC
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220724793
Principal investigator 1 GlaxoSmithKline, LLC. $2,081.40 10/23/2025 Non-covered Recipient Entity
ST FRANCIS HOLDINGS LLC
A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF No dispute reported 06/30/2026 1192165368
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $198.72 10/17/2025 Non-covered Recipient Entity
ST FRANCIS MEDICAL INSTITUTE
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184251379
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,215.92 10/17/2025 Non-covered Recipient Entity
ST FRANCIS MEDICAL INSTITUTE
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184251381
Principal investigator 1 AstraZeneca Pharmaceuticals LP $13,397.50 10/02/2025 Non-covered Recipient Entity
SAINT FRANCIS SLEEP ALLERGY AND LUNG INSTITUTE
A Multicenter, Randomized, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab 100 mg in Patients with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) with a History of Frequent COPD Exacerbations and Elevated Peripheral Blood Eosinophils (RESOLUTE) No dispute reported 06/30/2026 1185555820
Principal investigator 1 Boehringer Ingelheim International GmbH $34.63 10/01/2025 Non-covered Recipient Entity
ST FRANCIS MEDCL INST
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220622746
Principal investigator 1 Boehringer Ingelheim International GmbH $3.86 10/01/2025 Non-covered Recipient Entity
ST FRANCIS MEDCL INST
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220622748
Principal investigator 1 Boehringer Ingelheim International GmbH $3.86 10/01/2025 Non-covered Recipient Entity
ST FRANCIS MEDCL INST
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220622750
Principal investigator 1 Boehringer Ingelheim International GmbH $34.63 10/01/2025 Non-covered Recipient Entity
ST FRANCIS MEDCL INST
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220622752
Principal investigator 1 Boehringer Ingelheim International GmbH $15.39 10/01/2025 Non-covered Recipient Entity
St Francis Sleep Allergy And Lung Institute LLC
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220724763
Principal investigator 1 Boehringer Ingelheim International GmbH $7.08 10/01/2025 Non-covered Recipient Entity
St Francis Sleep Allergy And Lung Institute LLC
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220724765
Principal investigator 1 Boehringer Ingelheim International GmbH $11.29 10/01/2025 Non-covered Recipient Entity
St Francis Sleep Allergy And Lung Institute LLC
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220724767
Principal investigator 1 Boehringer Ingelheim International GmbH $94.42 10/01/2025 Non-covered Recipient Entity
St Francis Sleep Allergy And Lung Institute LLC
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220724769
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $850.00 09/26/2025 Non-covered Recipient Entity
ST FRANCIS MEDICAL INSTITUTE
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184243125
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,483.00 09/26/2025 Non-covered Recipient Entity
ST FRANCIS MEDICAL INSTITUTE
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184243127
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,660.00 09/26/2025 Non-covered Recipient Entity
ST FRANCIS MEDICAL INSTITUTE
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184243129
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $974.00 09/26/2025 Non-covered Recipient Entity
ST FRANCIS MEDICAL INSTITUTE
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184243131
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,000.00 09/24/2025 Non-covered Recipient Entity
St Francis Holdings LLC St Francis Medical Institute
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) No dispute reported 06/30/2026 1220799568
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,810.00 09/24/2025 Non-covered Recipient Entity
St Francis Holdings LLC St Francis Medical Institute
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) No dispute reported 06/30/2026 1220799570
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $27.60 09/24/2025 Non-covered Recipient Entity
St Francis Holdings LLC St Francis Medical Institute
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) No dispute reported 06/30/2026 1220799572
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,500.00 09/24/2025 Non-covered Recipient Entity
St Francis Holdings LLC St Francis Medical Institute
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) No dispute reported 06/30/2026 1220799574
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $207.60 09/24/2025 Non-covered Recipient Entity
St Francis Holdings LLC St Francis Medical Institute
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) No dispute reported 06/30/2026 1220799576
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,710.04 09/18/2025 Non-covered Recipient Entity
ST FRANCIS MEDICAL INSTITUTE
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184240292
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,463.20 09/18/2025 Non-covered Recipient Entity
ST FRANCIS MEDICAL INSTITUTE
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184240294
Principal investigator 1 Mannkind Corporation $4,922.43 09/16/2025 Non-covered Recipient Entity
ST FRANCIS MEDICAL INSTITUTE
ICON-1 PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF TREATMENT WITH MNKD-101, CLOFAZAMINE INHALATION SUSPENSION No dispute reported 06/30/2026 1250898580
Principal investigator 1 United Therapeutics Corporation $2,208.00 09/10/2025 Non-covered Recipient Entity
St Francis Holdings LLC
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242388305
Principal investigator 1 GlaxoSmithKline, LLC. $9,222.60 09/08/2025 Non-covered Recipient Entity
ST FRANCIS HOLDINGS LLC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192163809
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $276.00 09/04/2025 Non-covered Recipient Entity
St Francis Holdings LLC St Francis Medical Institute
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) No dispute reported 06/30/2026 1220799549
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $400.00 09/04/2025 Non-covered Recipient Entity
St Francis Holdings LLC St Francis Medical Institute
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) No dispute reported 06/30/2026 1220799551
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $400.00 09/04/2025 Non-covered Recipient Entity
St Francis Holdings LLC St Francis Medical Institute
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) No dispute reported 06/30/2026 1220799553
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $27.60 09/04/2025 Non-covered Recipient Entity
St Francis Holdings LLC St Francis Medical Institute
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) No dispute reported 06/30/2026 1220799555
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $27.60 09/04/2025 Non-covered Recipient Entity
St Francis Holdings LLC St Francis Medical Institute
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) No dispute reported 06/30/2026 1220799557
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $27.60 09/04/2025 Non-covered Recipient Entity
St Francis Holdings LLC St Francis Medical Institute
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) No dispute reported 06/30/2026 1220799559
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $27.60 09/04/2025 Non-covered Recipient Entity
St Francis Holdings LLC St Francis Medical Institute
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) No dispute reported 06/30/2026 1220799561
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $27.60 09/04/2025 Non-covered Recipient Entity
St Francis Holdings LLC St Francis Medical Institute
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) No dispute reported 06/30/2026 1220799564
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $27.60 09/04/2025 Non-covered Recipient Entity
St Francis Holdings LLC St Francis Medical Institute
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) No dispute reported 06/30/2026 1220799566
Principal investigator 1 Boehringer Ingelheim International GmbH $34.63 09/01/2025 Non-covered Recipient Entity
ST FRANCIS MEDCL INST
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220622738
Principal investigator 1 Boehringer Ingelheim International GmbH $3.86 09/01/2025 Non-covered Recipient Entity
ST FRANCIS MEDCL INST
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220622740
Principal investigator 1 Boehringer Ingelheim International GmbH $34.63 09/01/2025 Non-covered Recipient Entity
ST FRANCIS MEDCL INST
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220622742
Principal investigator 1 Boehringer Ingelheim International GmbH $3.86 09/01/2025 Non-covered Recipient Entity
ST FRANCIS MEDCL INST
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220622744
Principal investigator 1 Boehringer Ingelheim International GmbH $15.39 09/01/2025 Non-covered Recipient Entity
St Francis Sleep Allergy And Lung Institute LLC
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220724727
Principal investigator 1 Boehringer Ingelheim International GmbH $7.08 09/01/2025 Non-covered Recipient Entity
St Francis Sleep Allergy And Lung Institute LLC
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220724755
Principal investigator 1 Boehringer Ingelheim International GmbH $94.42 09/01/2025 Non-covered Recipient Entity
St Francis Sleep Allergy And Lung Institute LLC
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220724757
Principal investigator 1 Boehringer Ingelheim International GmbH $11.29 09/01/2025 Non-covered Recipient Entity
St Francis Sleep Allergy And Lung Institute LLC
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220724759
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $34.00 09/01/2025 Non-covered Recipient Entity
ST FRANCIS MEDCL INST
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220791663
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $232.00 09/01/2025 Non-covered Recipient Entity
ST FRANCIS MEDCL INST
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220791665
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $27.60 09/01/2025 Non-covered Recipient Entity
St Francis Holdings LLC St Francis Medical Institute
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) No dispute reported 06/30/2026 1220799612
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $27.60 09/01/2025 Non-covered Recipient Entity
St Francis Holdings LLC St Francis Medical Institute
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) No dispute reported 06/30/2026 1220799614
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $27.60 09/01/2025 Non-covered Recipient Entity
St Francis Holdings LLC St Francis Medical Institute
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) No dispute reported 06/30/2026 1220799616
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $27.60 09/01/2025 Non-covered Recipient Entity
St Francis Holdings LLC St Francis Medical Institute
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) No dispute reported 06/30/2026 1220799618
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $27.60 09/01/2025 Non-covered Recipient Entity
St Francis Holdings LLC St Francis Medical Institute
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) No dispute reported 06/30/2026 1220799620
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,250.00 08/28/2025 Non-covered Recipient Entity
St Francis Holdings LLC St Francis Medical Institute
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220799598
Principal investigator 1 GlaxoSmithKline, LLC. $693.80 08/27/2025 Non-covered Recipient Entity
ST FRANCIS HOLDINGS LLC
A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF No dispute reported 06/30/2026 1192163821
Principal investigator 1 United Therapeutics Corporation $483.00 08/27/2025 Non-covered Recipient Entity
St Francis Holdings LLC
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242388295
Principal investigator 1 AstraZeneca Pharmaceuticals LP $29,015.80 08/22/2025 Non-covered Recipient Entity
SAINT FRANCIS SLEEP ALLERGY AND LUNG INSTITUTE
Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmonary Disease COPD No dispute reported 06/30/2026 1185555826
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,858.50 08/21/2025 Non-covered Recipient Entity
St Francis Holdings LLC St Francis Medical Institute
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220799596
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $557.66 08/20/2025 Non-covered Recipient Entity
ST FRANCIS MEDICAL INSTITUTE
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184228859
Principal investigator 1 Insmed, Inc. $6,888.84 08/14/2025 Non-covered Recipient Entity
St. Francis Medical Institute - Clinedge - PPDS
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646634
Principal investigator 1 Insmed, Inc. $0.44 08/14/2025 Non-covered Recipient Entity
St. Francis Medical Institute - Clinedge - PPDS
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646638
Principal investigator 1 Insmed, Inc. $0.46 08/14/2025 Non-covered Recipient Entity
St. Francis Medical Institute - Clinedge - PPDS
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646642
Principal investigator 1 Mannkind Corporation $17,053.36 08/12/2025 Non-covered Recipient Entity
ST FRANCIS MEDICAL INSTITUTE
ICON-1 PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF TREATMENT WITH MNKD-101, CLOFAZAMINE INHALATION SUSPENSION No dispute reported 06/30/2026 1250898540
Principal investigator 1 Mannkind Corporation $10,046.40 08/12/2025 Non-covered Recipient Entity
ST FRANCIS MEDICAL INSTITUTE
ICON-1 PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF TREATMENT WITH MNKD-101, CLOFAZAMINE INHALATION SUSPENSION No dispute reported 06/30/2026 1250898542
Principal investigator 1 Insmed, Inc. $6,888.84 08/07/2025 Non-covered Recipient Entity
St. Francis Medical Institute - Clinedge - PPDS
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646636
Principal investigator 1 Insmed, Inc. $0.44 08/07/2025 Non-covered Recipient Entity
St. Francis Medical Institute - Clinedge - PPDS
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646640
Principal investigator 1 Insmed, Inc. $0.46 08/07/2025 Non-covered Recipient Entity
St. Francis Medical Institute - Clinedge - PPDS
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646644
Principal investigator 1 Boehringer Ingelheim International GmbH $34.63 08/01/2025 Non-covered Recipient Entity
ST FRANCIS MEDCL INST
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220622730
Principal investigator 1 Boehringer Ingelheim International GmbH $3.86 08/01/2025 Non-covered Recipient Entity
ST FRANCIS MEDCL INST
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220622732
Principal investigator 1 Boehringer Ingelheim International GmbH $34.63 08/01/2025 Non-covered Recipient Entity
ST FRANCIS MEDCL INST
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220622734
Principal investigator 1 Boehringer Ingelheim International GmbH $3.86 08/01/2025 Non-covered Recipient Entity
ST FRANCIS MEDCL INST
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220622736
Principal investigator 1 Boehringer Ingelheim International GmbH $15.39 08/01/2025 Non-covered Recipient Entity
St Francis Sleep Allergy And Lung Institute LLC
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220724729
Principal investigator 1 Boehringer Ingelheim International GmbH $335.63 08/01/2025 Non-covered Recipient Entity
St Francis Sleep Allergy And Lung Institute LLC
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220724731
Principal investigator 1 Boehringer Ingelheim International GmbH $7.08 08/01/2025 Non-covered Recipient Entity
St Francis Sleep Allergy And Lung Institute LLC
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220724739
Principal investigator 1 Boehringer Ingelheim International GmbH $11.29 08/01/2025 Non-covered Recipient Entity
St Francis Sleep Allergy And Lung Institute LLC
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220724741
Principal investigator 1 Boehringer Ingelheim International GmbH $94.42 08/01/2025 Non-covered Recipient Entity
St Francis Sleep Allergy And Lung Institute LLC
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220724743
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 08/01/2025 Non-covered Recipient Entity
St Francis Sleep Allergy And Lung Institute LLC
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220724745
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 08/01/2025 Non-covered Recipient Entity
St Francis Sleep Allergy And Lung Institute LLC
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220724747
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 08/01/2025 Non-covered Recipient Entity
St Francis Sleep Allergy And Lung Institute LLC
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220724749
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 08/01/2025 Non-covered Recipient Entity
St Francis Sleep Allergy And Lung Institute LLC
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220724751
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $34.00 08/01/2025 Non-covered Recipient Entity
ST FRANCIS MEDCL INST
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220791659
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $232.00 08/01/2025 Non-covered Recipient Entity
ST FRANCIS MEDCL INST
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220791661
Principal investigator 1 Genentech, Inc. $1,634.00 07/23/2025 Non-covered Recipient Entity
ST FRANCIS SLEEP ALLERGY AND LUNG INSTITUTE
Ph IIb of Astegolimab in COPD No dispute reported 06/30/2026 1211659163
Principal investigator 1 Genentech, Inc. $27,453.00 07/22/2025 Non-covered Recipient Entity
ST FRANCIS SLEEP ALLERGY AND LUNG INSTITUTE
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211659158
Principal investigator 1 Genentech, Inc. $550.00 07/09/2025 Non-covered Recipient Entity
ST FRANCIS SLEEP ALLERGY AND LUNG INSTITUTE
Ph IIb of Astegolimab in COPD No dispute reported 06/30/2026 1211659155
Principal investigator 1 United Therapeutics Corporation $3,229.20 07/08/2025 Non-covered Recipient Entity
St Francis Holdings LLC
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242388309
Principal investigator 1 Genentech, Inc. $309.00 07/02/2025 Non-covered Recipient Entity
ST FRANCIS SLEEP ALLERGY AND LUNG INSTITUTE
Ph IIb of Astegolimab in COPD No dispute reported 06/30/2026 1211659151
Principal investigator 1 Boehringer Ingelheim International GmbH $34.63 07/01/2025 Non-covered Recipient Entity
ST FRANCIS MEDCL INST
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220622722
Principal investigator 1 Boehringer Ingelheim International GmbH $3.86 07/01/2025 Non-covered Recipient Entity
ST FRANCIS MEDCL INST
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220622724
Principal investigator 1 Boehringer Ingelheim International GmbH $34.63 07/01/2025 Non-covered Recipient Entity
ST FRANCIS MEDCL INST
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220622726
Principal investigator 1 Boehringer Ingelheim International GmbH $3.86 07/01/2025 Non-covered Recipient Entity
ST FRANCIS MEDCL INST
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220622728
Principal investigator 1 Boehringer Ingelheim International GmbH $799.00 07/01/2025 Non-covered Recipient Entity
St Francis Sleep Allergy And Lung Institute LLC
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220724725
Principal investigator 1 Boehringer Ingelheim International GmbH $7.08 07/01/2025 Non-covered Recipient Entity
St Francis Sleep Allergy And Lung Institute LLC
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220724733
Principal investigator 1 Boehringer Ingelheim International GmbH $94.42 07/01/2025 Non-covered Recipient Entity
St Francis Sleep Allergy And Lung Institute LLC
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220724735
Principal investigator 1 Boehringer Ingelheim International GmbH $11.29 07/01/2025 Non-covered Recipient Entity
St Francis Sleep Allergy And Lung Institute LLC
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220724737
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 07/01/2025 Non-covered Recipient Entity
St Francis Sleep Allergy And Lung Institute LLC
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220724753
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 07/01/2025 Non-covered Recipient Entity
St Francis Sleep Allergy And Lung Institute LLC
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220724761
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $232.00 07/01/2025 Non-covered Recipient Entity
ST FRANCIS MEDCL INST
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220791655
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $34.00 07/01/2025 Non-covered Recipient Entity
ST FRANCIS MEDCL INST
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220791657
Principal investigator 1 United Therapeutics Corporation $331.20 06/25/2025 Non-covered Recipient Entity
St Francis Holdings LLC
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242388291
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9,500.00 06/24/2025 Non-covered Recipient Entity
ST FRANCIS MEDICAL INSTITUTE
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184210544
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,535.00 06/23/2025 Non-covered Recipient Entity
ST FRANCIS MEDICAL INSTITUTE
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184210340
Principal investigator 1 Insmed, Inc. $0.66 06/19/2025 Non-covered Recipient Entity
St. Francis Medical Institute - Clinedge - PPDS
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646620
Principal investigator 1 Insmed, Inc. $11,481.40 06/19/2025 Non-covered Recipient Entity
St. Francis Medical Institute - Clinedge - PPDS
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646624
Principal investigator 1 Insmed, Inc. $0.92 06/19/2025 Non-covered Recipient Entity
St. Francis Medical Institute - Clinedge - PPDS
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646628
Principal investigator 1 Insmed, Inc. $0.66 06/12/2025 Non-covered Recipient Entity
St. Francis Medical Institute - Clinedge - PPDS
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646622
Principal investigator 1 Insmed, Inc. $11,481.40 06/12/2025 Non-covered Recipient Entity
St. Francis Medical Institute - Clinedge - PPDS
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646626
Principal investigator 1 Insmed, Inc. $0.92 06/12/2025 Non-covered Recipient Entity
St. Francis Medical Institute - Clinedge - PPDS
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646630
Principal investigator 1 United Therapeutics Corporation $2,691.00 06/11/2025 Non-covered Recipient Entity
St Francis Holdings LLC
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242388307
Principal investigator 1 Boehringer Ingelheim International GmbH $34.63 06/01/2025 Non-covered Recipient Entity
ST FRANCIS MEDCL INST
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220622714
Principal investigator 1 Boehringer Ingelheim International GmbH $3.86 06/01/2025 Non-covered Recipient Entity
ST FRANCIS MEDCL INST
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220622716
Principal investigator 1 Boehringer Ingelheim International GmbH $3.86 06/01/2025 Non-covered Recipient Entity
ST FRANCIS MEDCL INST
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220622718
Principal investigator 1 Boehringer Ingelheim International GmbH $34.63 06/01/2025 Non-covered Recipient Entity
ST FRANCIS MEDCL INST
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220622720
Principal investigator 1 Boehringer Ingelheim International GmbH $7.08 06/01/2025 Non-covered Recipient Entity
St Francis Sleep Allergy And Lung Institute LLC
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220724713
Principal investigator 1 Boehringer Ingelheim International GmbH $94.42 06/01/2025 Non-covered Recipient Entity
St Francis Sleep Allergy And Lung Institute LLC
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220724715
Principal investigator 1 Boehringer Ingelheim International GmbH $11.29 06/01/2025 Non-covered Recipient Entity
St Francis Sleep Allergy And Lung Institute LLC
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220724717
Principal investigator 1 Boehringer Ingelheim International GmbH $785.00 06/01/2025 Non-covered Recipient Entity
St Francis Sleep Allergy And Lung Institute LLC
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220724719
Principal investigator 1 Boehringer Ingelheim International GmbH $69.90 06/01/2025 Non-covered Recipient Entity
St Francis Sleep Allergy And Lung Institute LLC
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220724721
Principal investigator 1 Boehringer Ingelheim International GmbH $13.28 06/01/2025 Non-covered Recipient Entity
St Francis Sleep Allergy And Lung Institute LLC
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220724723
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $232.00 06/01/2025 Non-covered Recipient Entity
ST FRANCIS MEDCL INST
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220791651
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $34.00 06/01/2025 Non-covered Recipient Entity
ST FRANCIS MEDCL INST
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220791653
Principal investigator 1 Genentech, Inc. $120.00 05/28/2025 Non-covered Recipient Entity
ST FRANCIS SLEEP ALLERGY AND LUNG INSTITUTE
Ph IIb of Astegolimab in COPD No dispute reported 06/30/2026 1211659115
Principal investigator 1 Genentech, Inc. $42.00 05/23/2025 Non-covered Recipient Entity
ST FRANCIS SLEEP ALLERGY AND LUNG INSTITUTE
Ph IIb of Astegolimab in COPD No dispute reported 06/30/2026 1211659085
Principal investigator 1 Genentech, Inc. $42.00 05/23/2025 Non-covered Recipient Entity
ST FRANCIS SLEEP ALLERGY AND LUNG INSTITUTE
Ph IIb of Astegolimab in COPD No dispute reported 06/30/2026 1211659118
Principal investigator 1 Genentech, Inc. $120.00 05/23/2025 Non-covered Recipient Entity
ST FRANCIS SLEEP ALLERGY AND LUNG INSTITUTE
Ph IIb of Astegolimab in COPD No dispute reported 06/30/2026 1211659121
Principal investigator 1 Genentech, Inc. $120.00 05/23/2025 Non-covered Recipient Entity
ST FRANCIS SLEEP ALLERGY AND LUNG INSTITUTE
Ph IIb of Astegolimab in COPD No dispute reported 06/30/2026 1211659129
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $498.00 05/16/2025 Non-covered Recipient Entity
St Francis Holdings LLC St Francis Medical Institute
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220799586
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,500.00 05/16/2025 Non-covered Recipient Entity
St Francis Holdings LLC St Francis Medical Institute
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220799588
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $51.00 05/16/2025 Non-covered Recipient Entity
St Francis Holdings LLC St Francis Medical Institute
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220799590
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,939.00 05/16/2025 Non-covered Recipient Entity
St Francis Holdings LLC St Francis Medical Institute
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220799592
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $8,900.00 05/16/2025 Non-covered Recipient Entity
St Francis Holdings LLC St Francis Medical Institute
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220799594
Principal investigator 1 Genentech, Inc. $51,485.00 05/13/2025 Non-covered Recipient Entity
ST FRANCIS SLEEP ALLERGY AND LUNG INSTITUTE
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211659101
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,135.70 05/09/2025 Non-covered Recipient Entity
St Francis Holdings LLC St Francis Medical Institute
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220799584
Principal investigator 1 United Therapeutics Corporation $1,524.90 05/07/2025 Non-covered Recipient Entity
St Francis Holdings LLC
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242388299
Principal investigator 1 Genentech, Inc. $2,399.00 05/02/2025 Non-covered Recipient Entity
ST FRANCIS SLEEP ALLERGY AND LUNG INSTITUTE
Ph IIb of Astegolimab in COPD No dispute reported 06/30/2026 1211659077
Principal investigator 1 Genentech, Inc. $120.00 05/02/2025 Non-covered Recipient Entity
ST FRANCIS SLEEP ALLERGY AND LUNG INSTITUTE
Ph IIb of Astegolimab in COPD No dispute reported 06/30/2026 1211659081
Principal investigator 1 Genentech, Inc. $2,399.00 05/02/2025 Non-covered Recipient Entity
ST FRANCIS SLEEP ALLERGY AND LUNG INSTITUTE
Ph IIb of Astegolimab in COPD No dispute reported 06/30/2026 1211659089
Principal investigator 1 Genentech, Inc. $120.00 05/02/2025 Non-covered Recipient Entity
ST FRANCIS SLEEP ALLERGY AND LUNG INSTITUTE
Ph IIb of Astegolimab in COPD No dispute reported 06/30/2026 1211659106
Principal investigator 1 Genentech, Inc. $120.00 05/02/2025 Non-covered Recipient Entity
ST FRANCIS SLEEP ALLERGY AND LUNG INSTITUTE
Ph IIb of Astegolimab in COPD No dispute reported 06/30/2026 1211659111
Principal investigator 1 Genentech, Inc. $2,399.00 05/02/2025 Non-covered Recipient Entity
ST FRANCIS SLEEP ALLERGY AND LUNG INSTITUTE
Ph IIb of Astegolimab in COPD No dispute reported 06/30/2026 1211659125
Principal investigator 1 Genentech, Inc. $2,399.00 05/02/2025 Non-covered Recipient Entity
ST FRANCIS SLEEP ALLERGY AND LUNG INSTITUTE
Ph IIb of Astegolimab in COPD No dispute reported 06/30/2026 1211659133
Principal investigator 1 Genentech, Inc. $2,399.00 05/02/2025 Non-covered Recipient Entity
ST FRANCIS SLEEP ALLERGY AND LUNG INSTITUTE
Ph IIb of Astegolimab in COPD No dispute reported 06/30/2026 1211659138
Principal investigator 1 Genentech, Inc. $2,399.00 05/02/2025 Non-covered Recipient Entity
ST FRANCIS SLEEP ALLERGY AND LUNG INSTITUTE
Ph IIb of Astegolimab in COPD No dispute reported 06/30/2026 1211659143
Principal investigator 1 Genentech, Inc. $2,399.00 05/02/2025 Non-covered Recipient Entity
ST FRANCIS SLEEP ALLERGY AND LUNG INSTITUTE
Ph IIb of Astegolimab in COPD No dispute reported 06/30/2026 1211659147
Principal investigator 1 Boehringer Ingelheim International GmbH $37.66 05/01/2025 Non-covered Recipient Entity
ST FRANCIS MEDCL INST
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220622698
Principal investigator 1 Boehringer Ingelheim International GmbH $37.66 05/01/2025 Non-covered Recipient Entity
ST FRANCIS MEDCL INST
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220622700
Principal investigator 1 Boehringer Ingelheim International GmbH $3.86 05/01/2025 Non-covered Recipient Entity
ST FRANCIS MEDCL INST
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220622702
Principal investigator 1 Boehringer Ingelheim International GmbH $34.63 05/01/2025 Non-covered Recipient Entity
ST FRANCIS MEDCL INST
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220622704
Principal investigator 1 Boehringer Ingelheim International GmbH $34.63 05/01/2025 Non-covered Recipient Entity
ST FRANCIS MEDCL INST
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220622706
Principal investigator 1 Boehringer Ingelheim International GmbH $3.86 05/01/2025 Non-covered Recipient Entity
ST FRANCIS MEDCL INST
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220622708
Principal investigator 1 Boehringer Ingelheim International GmbH $3.86 05/01/2025 Non-covered Recipient Entity
ST FRANCIS MEDCL INST
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220622710
Principal investigator 1 Boehringer Ingelheim International GmbH $34.63 05/01/2025 Non-covered Recipient Entity
ST FRANCIS MEDCL INST
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220622712
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $232.00 05/01/2025 Non-covered Recipient Entity
ST FRANCIS MEDCL INST
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220791647
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $34.00 05/01/2025 Non-covered Recipient Entity
ST FRANCIS MEDCL INST
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220791649
Principal investigator 1 Genentech, Inc. $8,554.00 05/01/2025 Non-covered Recipient Entity
ST FRANCIS SLEEP ALLERGY AND LUNG INSTITUTE
Ph IIb of Astegolimab in COPD No dispute reported 06/30/2026 1211659093
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $557.66 04/28/2025 Non-covered Recipient Entity
ST FRANCIS MEDICAL INSTITUTE
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184190505
Principal investigator 1 Amgen Inc. $34,169.00 04/24/2025 Non-covered Recipient Entity
ST FRANCIS HOLDINGS LLC ST FRANCIS SLEEP ALLERGY AND LUNG INSTITUTE LLC
A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose Ranging Study to Assess the Efficacy and Safety of Rocatinlimab in Adult Subjects With Moderate-to-severe Asthma No dispute reported 06/30/2026 1246648605
Principal investigator 1 Mannkind Corporation $15,638.86 04/18/2025 Non-covered Recipient Entity
ST FRANCIS MEDICAL INSTITUTE
ICON-1 PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF TREATMENT WITH MNKD-101, CLOFAZAMINE INHALATION SUSPENSION No dispute reported 06/30/2026 1250898488
Principal investigator 1 Mannkind Corporation $15,312.83 04/18/2025 Non-covered Recipient Entity
ST FRANCIS MEDICAL INSTITUTE
ICON-1 PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF TREATMENT WITH MNKD-101, CLOFAZAMINE INHALATION SUSPENSION No dispute reported 06/30/2026 1250898490
Principal investigator 1 Mannkind Corporation $18,578.26 04/18/2025 Non-covered Recipient Entity
ST FRANCIS MEDICAL INSTITUTE
ICON-1 PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF TREATMENT WITH MNKD-101, CLOFAZAMINE INHALATION SUSPENSION No dispute reported 06/30/2026 1250898492
Principal investigator 1 GlaxoSmithKline, LLC. $40.00 04/17/2025 Non-covered Recipient Entity
ST FRANCIS HOLDINGS LLC
A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF No dispute reported 06/30/2026 1192163817
Principal investigator 1 GlaxoSmithKline, LLC. $750.03 04/17/2025 Non-covered Recipient Entity
ST FRANCIS HOLDINGS LLC
A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF No dispute reported 06/30/2026 1192163825
Principal investigator 1 GlaxoSmithKline, LLC. $8,900.00 04/17/2025 Non-covered Recipient Entity
ST FRANCIS HOLDINGS LLC
A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF No dispute reported 06/30/2026 1192165386
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,688.40 04/10/2025 Non-covered Recipient Entity
St Francis Holdings LLC St Francis Medical Institute
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) No dispute reported 06/30/2026 1220799610
Principal investigator 1 Insmed, Inc. $6,888.84 04/09/2025 Non-covered Recipient Entity
St. Francis Medical Institute - Clinedge - PPDS
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646616
Principal investigator 1 United Therapeutics Corporation $897.00 04/09/2025 Non-covered Recipient Entity
St Francis Holdings LLC
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242388297
Principal investigator 1 Insmed, Inc. $0.44 04/02/2025 Non-covered Recipient Entity
St. Francis Medical Institute - Clinedge - PPDS
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646614
Principal investigator 1 Insmed, Inc. $6,888.84 04/02/2025 Non-covered Recipient Entity
St. Francis Medical Institute - Clinedge - PPDS
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646618
Principal investigator 1 Insmed, Inc. $0.46 04/02/2025 Non-covered Recipient Entity
St. Francis Medical Institute - Clinedge - PPDS
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646632
Principal investigator 1 Boehringer Ingelheim International GmbH $11.57 04/01/2025 Non-covered Recipient Entity
ST FRANCIS MEDCL INST
PDE4 Phase III trial in IPF patients No dispute reported 06/30/2026 1220622798
Principal investigator 1 Boehringer Ingelheim International GmbH $103.87 04/01/2025 Non-covered Recipient Entity
ST FRANCIS MEDCL INST
PDE4 Phase III trial in IPF patients No dispute reported 06/30/2026 1220622800
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $232.00 04/01/2025 Non-covered Recipient Entity
ST FRANCIS MEDCL INST
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220791643
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $34.00 04/01/2025 Non-covered Recipient Entity
ST FRANCIS MEDCL INST
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220791645
Principal investigator 1 Genentech, Inc. $34,363.00 04/01/2025 Non-covered Recipient Entity
ST FRANCIS SLEEP ALLERGY AND LUNG INSTITUTE
Ph IIb of Astegolimab in COPD No dispute reported 06/30/2026 1211659097
Principal investigator 1 Mannkind Corporation $255.00 03/28/2025 Non-covered Recipient Entity
ST FRANCIS MEDICAL INSTITUTE
ICON-1 PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF TREATMENT WITH MNKD-101, CLOFAZAMINE INHALATION SUSPENSION No dispute reported 06/30/2026 1250898456
Principal investigator 1 Mannkind Corporation $255.00 03/28/2025 Non-covered Recipient Entity
ST FRANCIS MEDICAL INSTITUTE
ICON-1 PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF TREATMENT WITH MNKD-101, CLOFAZAMINE INHALATION SUSPENSION No dispute reported 06/30/2026 1250898458
Principal investigator 1 Mannkind Corporation $255.00 03/28/2025 Non-covered Recipient Entity
ST FRANCIS MEDICAL INSTITUTE
ICON-1 PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF TREATMENT WITH MNKD-101, CLOFAZAMINE INHALATION SUSPENSION No dispute reported 06/30/2026 1250898460
Principal investigator 1 Mannkind Corporation $3,350.00 03/28/2025 Non-covered Recipient Entity
ST FRANCIS MEDICAL INSTITUTE
ICON-1 PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF TREATMENT WITH MNKD-101, CLOFAZAMINE INHALATION SUSPENSION No dispute reported 06/30/2026 1250898462
Principal investigator 1 Mannkind Corporation $2,075.00 03/28/2025 Non-covered Recipient Entity
ST FRANCIS MEDICAL INSTITUTE
ICON-1 PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF TREATMENT WITH MNKD-101, CLOFAZAMINE INHALATION SUSPENSION No dispute reported 06/30/2026 1250898464
Principal investigator 1 Mannkind Corporation $2,025.00 03/28/2025 Non-covered Recipient Entity
ST FRANCIS MEDICAL INSTITUTE
ICON-1 PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF TREATMENT WITH MNKD-101, CLOFAZAMINE INHALATION SUSPENSION No dispute reported 06/30/2026 1250898466
Principal investigator 1 Mannkind Corporation $150.00 03/28/2025 Non-covered Recipient Entity
ST FRANCIS MEDICAL INSTITUTE
ICON-1 PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF TREATMENT WITH MNKD-101, CLOFAZAMINE INHALATION SUSPENSION No dispute reported 06/30/2026 1250898468
Principal investigator 1 Mannkind Corporation $1,200.00 03/28/2025 Non-covered Recipient Entity
ST FRANCIS MEDICAL INSTITUTE
ICON-1 PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF TREATMENT WITH MNKD-101, CLOFAZAMINE INHALATION SUSPENSION No dispute reported 06/30/2026 1250898470
Principal investigator 1 Insmed, Inc. $0.88 03/27/2025 Non-covered Recipient Entity
St. Francis Medical Institute - Clinedge - PPDS
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646544
Principal investigator 1 Insmed, Inc. $16,073.96 03/27/2025 Non-covered Recipient Entity
St. Francis Medical Institute - Clinedge - PPDS
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646548
Principal investigator 1 Insmed, Inc. $0.92 03/27/2025 Non-covered Recipient Entity
St. Francis Medical Institute - Clinedge - PPDS
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646566
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,620.00 03/25/2025 Non-covered Recipient Entity
St Francis Holdings LLC St Francis Medical Institute
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220799582
Principal investigator 1 GlaxoSmithKline, LLC. $5,896.05 03/20/2025 Non-covered Recipient Entity
ST FRANCIS HOLDINGS LLC
A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF No dispute reported 06/30/2026 1192163813
Principal investigator 1 Insmed, Inc. $1.33 03/20/2025 Non-covered Recipient Entity
St. Francis Medical Institute - Clinedge - PPDS
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646546
Principal investigator 1 Insmed, Inc. $16,073.96 03/20/2025 Non-covered Recipient Entity
St. Francis Medical Institute - Clinedge - PPDS
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646550
Principal investigator 1 Insmed, Inc. $6,888.84 03/20/2025 Non-covered Recipient Entity
St. Francis Medical Institute - Clinedge - PPDS
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646552
Principal investigator 1 Insmed, Inc. $1.38 03/20/2025 Non-covered Recipient Entity
St. Francis Medical Institute - Clinedge - PPDS
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646568
Principal investigator 1 Paratek Pharmaceuticals, Inc. $228.00 03/20/2025 Non-covered Recipient Entity
ST FRANCIS HOLDINGS LLC
A Ph. 2, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety, & Tolerability of Oral Omadacycline in Adults With NTM Pulmonary Disease Caused by Mycobacterium Abscessus Complex No dispute reported 06/30/2026 1181711142
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,750.50 03/18/2025 Non-covered Recipient Entity
St Francis Holdings LLC St Francis Medical Institute
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220799580
Principal investigator 1 Paratek Pharmaceuticals, Inc. $3,122.94 03/13/2025 Non-covered Recipient Entity
ST FRANCIS HOLDINGS LLC
A Ph. 2, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety, & Tolerability of Oral Omadacycline in Adults With NTM Pulmonary Disease Caused by Mycobacterium Abscessus Complex No dispute reported 06/30/2026 1181711136
Principal investigator 1 GlaxoSmithKline, LLC. $1,576.73 03/07/2025 Non-covered Recipient Entity
ST FRANCIS SLEEP ALLERGY AND LUNG INSTITUTE
A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONT No dispute reported 06/30/2026 1192108973
Principal investigator 1 GlaxoSmithKline, LLC. $804.00 03/07/2025 Non-covered Recipient Entity
ST FRANCIS HOLDINGS LLC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192165377
Principal investigator 1 Paratek Pharmaceuticals, Inc. $2,985.53 03/06/2025 Non-covered Recipient Entity
ST FRANCIS HOLDINGS LLC
A Ph. 2, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety, & Tolerability of Oral Omadacycline in Adults With NTM Pulmonary Disease Caused by Mycobacterium Abscessus Complex No dispute reported 06/30/2026 1181711118
Principal investigator 1 Paratek Pharmaceuticals, Inc. $4,524.00 03/06/2025 Non-covered Recipient Entity
ST FRANCIS HOLDINGS LLC
A Ph. 2, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety, & Tolerability of Oral Omadacycline in Adults With NTM Pulmonary Disease Caused by Mycobacterium Abscessus Complex No dispute reported 06/30/2026 1181711120
Principal investigator 1 Boehringer Ingelheim International GmbH $103.87 03/01/2025 Non-covered Recipient Entity
ST FRANCIS MEDCL INST
PDE4 Phase III trial in IPF patients No dispute reported 06/30/2026 1220622794
Principal investigator 1 Boehringer Ingelheim International GmbH $11.57 03/01/2025 Non-covered Recipient Entity
ST FRANCIS MEDCL INST
PDE4 Phase III trial in IPF patients No dispute reported 06/30/2026 1220622796
Principal investigator 1 Boehringer Ingelheim International GmbH $35.79 03/01/2025 Non-covered Recipient Entity
ST FRANCIS MEDCL INST
PDE4 Phase III trial in PF-ILD No dispute reported 06/30/2026 1220622802
Principal investigator 1 Boehringer Ingelheim International GmbH $35.79 03/01/2025 Non-covered Recipient Entity
ST FRANCIS MEDCL INST
PDE4 Phase III trial in PF-ILD No dispute reported 06/30/2026 1220622804
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $232.00 03/01/2025 Non-covered Recipient Entity
ST FRANCIS MEDCL INST
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) No dispute reported 06/30/2026 1220791639
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $34.00 03/01/2025 Non-covered Recipient Entity
ST FRANCIS MEDCL INST
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) No dispute reported 06/30/2026 1220791641
Principal investigator 1 Insmed, Inc. $0.44 02/27/2025 Non-covered Recipient Entity
St. Francis Medical Institute - Clinedge - PPDS
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646540
Principal investigator 1 Insmed, Inc. $6,888.84 02/27/2025 Non-covered Recipient Entity
St. Francis Medical Institute - Clinedge - PPDS
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646554
Principal investigator 1 Insmed, Inc. $0.46 02/27/2025 Non-covered Recipient Entity
St. Francis Medical Institute - Clinedge - PPDS
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646558
Principal investigator 1 United Therapeutics Corporation $1,794.00 02/26/2025 Non-covered Recipient Entity
St Francis Holdings LLC
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242388287
Principal investigator 1 Boehringer Ingelheim International GmbH $36.50 02/25/2025 Non-covered Recipient Entity
ST FRANCIS MEDCL INST
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220622692
Principal investigator 1 Boehringer Ingelheim International GmbH $1.68 02/25/2025 Non-covered Recipient Entity
ST FRANCIS MEDCL INST
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220622694
Principal investigator 1 Boehringer Ingelheim International GmbH $1.50 02/25/2025 Non-covered Recipient Entity
ST FRANCIS MEDCL INST
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220622696
Principal investigator 1 Boehringer Ingelheim International GmbH $36.50 02/25/2025 Non-covered Recipient Entity
ST FRANCIS MEDCL INST
PDE4 Phase III trial in PF-ILD No dispute reported 06/30/2026 1220622824
Principal investigator 1 Boehringer Ingelheim International GmbH $14.02 02/25/2025 Non-covered Recipient Entity
ST FRANCIS MEDCL INST
PDE4 Phase III trial in PF-ILD No dispute reported 06/30/2026 1220622826
Principal investigator 1 Boehringer Ingelheim International GmbH $4.44 02/25/2025 Non-covered Recipient Entity
ST FRANCIS MEDCL INST
PDE4 Phase III trial in PF-ILD No dispute reported 06/30/2026 1220622828
Principal investigator 1 Boehringer Ingelheim International GmbH $4.44 02/25/2025 Non-covered Recipient Entity
ST FRANCIS MEDCL INST
PDE4 Phase III trial in PF-ILD No dispute reported 06/30/2026 1220622830
Principal investigator 1 Boehringer Ingelheim International GmbH $4.44 02/25/2025 Non-covered Recipient Entity
ST FRANCIS MEDCL INST
PDE4 Phase III trial in PF-ILD No dispute reported 06/30/2026 1220622832
Principal investigator 1 Boehringer Ingelheim International GmbH $4.44 02/25/2025 Non-covered Recipient Entity
ST FRANCIS MEDCL INST
PDE4 Phase III trial in PF-ILD No dispute reported 06/30/2026 1220622834
Principal investigator 1 Boehringer Ingelheim International GmbH $1.60 02/25/2025 Non-covered Recipient Entity
ST FRANCIS MEDCL INST
PDE4 Phase III trial in PF-ILD No dispute reported 06/30/2026 1220622836
Principal investigator 1 AstraZeneca Pharmaceuticals LP $42,622.22 02/24/2025 Non-covered Recipient Entity
ST FRANCIS INSTITUTE
The CHRONICLE Study is a multi center,non interventional,prospective cohort study of adults with severe asthma who do not achieve control with high-dose ICS therapy with additional controllers and or require systemic corticosteroid or monoclonal antibod No dispute reported 06/30/2026 1185555824
Principal investigator 1 Insmed, Inc. $1,304.55 02/21/2025 Non-covered Recipient Entity
St. Francis Medical Institute - Clinedge - PPDS
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646596
Principal investigator 1 Insmed, Inc. $1,304.55 02/21/2025 Non-covered Recipient Entity
St. Francis Medical Institute - Clinedge - PPDS
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646598
Principal investigator 1 Insmed, Inc. $1,374.75 02/21/2025 Non-covered Recipient Entity
St. Francis Medical Institute - Clinedge - PPDS
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646600
Principal investigator 1 Insmed, Inc. $298.35 02/21/2025 Non-covered Recipient Entity
St. Francis Medical Institute - Clinedge - PPDS
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646602
Principal investigator 1 Insmed, Inc. $298.35 02/21/2025 Non-covered Recipient Entity
St. Francis Medical Institute - Clinedge - PPDS
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646604
Principal investigator 1 Insmed, Inc. $70.20 02/21/2025 Non-covered Recipient Entity
St. Francis Medical Institute - Clinedge - PPDS
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646606
Principal investigator 1 Insmed, Inc. $298.35 02/21/2025 Non-covered Recipient Entity
St. Francis Medical Institute - Clinedge - PPDS
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646608
Principal investigator 1 Insmed, Inc. $263.25 02/21/2025 Non-covered Recipient Entity
St. Francis Medical Institute - Clinedge - PPDS
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646610
Principal investigator 1 Insmed, Inc. $46.80 02/21/2025 Non-covered Recipient Entity
St. Francis Medical Institute - Clinedge - PPDS
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646612
Principal investigator 1 Insmed, Inc. $0.44 02/20/2025 Non-covered Recipient Entity
St. Francis Medical Institute - Clinedge - PPDS
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646542
Principal investigator 1 Insmed, Inc. $6,888.84 02/20/2025 Non-covered Recipient Entity
St. Francis Medical Institute - Clinedge - PPDS
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646556
Principal investigator 1 Insmed, Inc. $0.46 02/20/2025 Non-covered Recipient Entity
St. Francis Medical Institute - Clinedge - PPDS
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646560
Principal investigator 1 United Therapeutics Corporation $2,960.10 02/12/2025 Non-covered Recipient Entity
St Francis Holdings LLC
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242388289
Principal investigator 1 Genentech, Inc. $40,683.00 02/06/2025 Non-covered Recipient Entity
ST FRANCIS SLEEP ALLERGY AND LUNG INSTITUTE
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211659074
Principal investigator 1 Insmed, Inc. $0.92 02/05/2025 Non-covered Recipient Entity
St. Francis Medical Institute - Clinedge - PPDS
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646562
Principal investigator 1 Boehringer Ingelheim International GmbH $11.57 02/01/2025 Non-covered Recipient Entity
ST FRANCIS MEDCL INST
PDE4 Phase III trial in IPF patients No dispute reported 06/30/2026 1220622786
Principal investigator 1 Boehringer Ingelheim International GmbH $103.87 02/01/2025 Non-covered Recipient Entity
ST FRANCIS MEDCL INST
PDE4 Phase III trial in IPF patients No dispute reported 06/30/2026 1220622788
Principal investigator 1 Boehringer Ingelheim International GmbH $11.57 02/01/2025 Non-covered Recipient Entity
ST FRANCIS MEDCL INST
PDE4 Phase III trial in IPF patients No dispute reported 06/30/2026 1220622790
Principal investigator 1 Boehringer Ingelheim International GmbH $103.87 02/01/2025 Non-covered Recipient Entity
ST FRANCIS MEDCL INST
PDE4 Phase III trial in IPF patients No dispute reported 06/30/2026 1220622792
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $34.00 02/01/2025 Non-covered Recipient Entity
ST FRANCIS MEDCL INST
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) No dispute reported 06/30/2026 1220791635
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $232.00 02/01/2025 Non-covered Recipient Entity
ST FRANCIS MEDCL INST
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) No dispute reported 06/30/2026 1220791637
Principal investigator 1 GlaxoSmithKline, LLC. $1,179.21 01/30/2025 Non-covered Recipient Entity
ST FRANCIS HOLDINGS LLC
A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF No dispute reported 06/30/2026 1192165381
Principal investigator 1 Amgen Inc. $3,265.72 01/27/2025 Non-covered Recipient Entity
ST FRANCIS MEDICAL INSTITUTE
A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose Ranging Study to Assess the Efficacy and Safety of Rocatinlimab in Adult Subjects With Moderate-to-severe Asthma No dispute reported 06/30/2026 1246648608
Principal investigator 1 Boehringer Ingelheim International GmbH $23.32 01/27/2025 Non-covered Recipient Entity
ST FRANCIS MEDCL INST
PDE4 Phase III trial in PF-ILD No dispute reported 06/30/2026 1220622806
Principal investigator 1 Boehringer Ingelheim International GmbH $99.90 01/27/2025 Non-covered Recipient Entity
ST FRANCIS MEDCL INST
PDE4 Phase III trial in PF-ILD No dispute reported 06/30/2026 1220622808
Principal investigator 1 Boehringer Ingelheim International GmbH $219.00 01/27/2025 Non-covered Recipient Entity
ST FRANCIS MEDCL INST
PDE4 Phase III trial in PF-ILD No dispute reported 06/30/2026 1220622810
Principal investigator 1 Boehringer Ingelheim International GmbH $28.04 01/27/2025 Non-covered Recipient Entity
ST FRANCIS MEDCL INST
PDE4 Phase III trial in PF-ILD No dispute reported 06/30/2026 1220622812
Principal investigator 1 Boehringer Ingelheim International GmbH $22.20 01/27/2025 Non-covered Recipient Entity
ST FRANCIS MEDCL INST
PDE4 Phase III trial in PF-ILD No dispute reported 06/30/2026 1220622814
Principal investigator 1 Boehringer Ingelheim International GmbH $22.20 01/27/2025 Non-covered Recipient Entity
ST FRANCIS MEDCL INST
PDE4 Phase III trial in PF-ILD No dispute reported 06/30/2026 1220622816
Principal investigator 1 Boehringer Ingelheim International GmbH $22.20 01/27/2025 Non-covered Recipient Entity
ST FRANCIS MEDCL INST
PDE4 Phase III trial in PF-ILD No dispute reported 06/30/2026 1220622818
Principal investigator 1 Boehringer Ingelheim International GmbH $22.20 01/27/2025 Non-covered Recipient Entity
ST FRANCIS MEDCL INST
PDE4 Phase III trial in PF-ILD No dispute reported 06/30/2026 1220622820
Principal investigator 1 Boehringer Ingelheim International GmbH $3.20 01/27/2025 Non-covered Recipient Entity
ST FRANCIS MEDCL INST
PDE4 Phase III trial in PF-ILD No dispute reported 06/30/2026 1220622822
Principal investigator 1 Insmed, Inc. $1,567.80 01/24/2025 Non-covered Recipient Entity
St. Francis Medical Institute - Clinedge - PPDS
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646570
Principal investigator 1 Insmed, Inc. $1,567.80 01/24/2025 Non-covered Recipient Entity
St. Francis Medical Institute - Clinedge - PPDS
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646572
Principal investigator 1 Insmed, Inc. $1,567.80 01/24/2025 Non-covered Recipient Entity
St. Francis Medical Institute - Clinedge - PPDS
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646574
Principal investigator 1 Insmed, Inc. $1,714.05 01/24/2025 Non-covered Recipient Entity
St. Francis Medical Institute - Clinedge - PPDS
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646576
Principal investigator 1 Insmed, Inc. $1,257.75 01/24/2025 Non-covered Recipient Entity
St. Francis Medical Institute - Clinedge - PPDS
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646578
Principal investigator 1 Insmed, Inc. $1,374.75 01/24/2025 Non-covered Recipient Entity
St. Francis Medical Institute - Clinedge - PPDS
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646580
Principal investigator 1 Insmed, Inc. $1,374.75 01/24/2025 Non-covered Recipient Entity
St. Francis Medical Institute - Clinedge - PPDS
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646582
Principal investigator 1 Insmed, Inc. $298.35 01/24/2025 Non-covered Recipient Entity
St. Francis Medical Institute - Clinedge - PPDS
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646584
Principal investigator 1 Insmed, Inc. $298.35 01/24/2025 Non-covered Recipient Entity
St. Francis Medical Institute - Clinedge - PPDS
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646586
Principal investigator 1 Insmed, Inc. $298.35 01/24/2025 Non-covered Recipient Entity
St. Francis Medical Institute - Clinedge - PPDS
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646588
Principal investigator 1 Insmed, Inc. $298.35 01/24/2025 Non-covered Recipient Entity
St. Francis Medical Institute - Clinedge - PPDS
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646590
Principal investigator 1 Insmed, Inc. $298.35 01/24/2025 Non-covered Recipient Entity
St. Francis Medical Institute - Clinedge - PPDS
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646592
Principal investigator 1 Insmed, Inc. $263.25 01/24/2025 Non-covered Recipient Entity
St. Francis Medical Institute - Clinedge - PPDS
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646594
Principal investigator 1 Insmed, Inc. $0.46 01/23/2025 Non-covered Recipient Entity
St. Francis Medical Institute - Clinedge - PPDS
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646564
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,736.80 01/21/2025 Non-covered Recipient Entity
St Francis Holdings LLC St Francis Medical Institute
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) No dispute reported 06/30/2026 1220799608
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $6,539.00 01/13/2025 Non-covered Recipient Entity
Saint Francis Sleep Allergy And Lung Institute
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1235994111
Principal investigator 1 GlaxoSmithKline, LLC. $2,075.75 01/13/2025 Non-covered Recipient Entity
ST FRANCIS HOLDINGS LLC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192165373
Principal investigator 1 Insmed, Inc. $1.33 01/13/2025 Non-covered Recipient Entity
St. Francis Medical Institute - Clinedge - PPDS
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646538
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $297,116.81 01/09/2025 Non-covered Recipient Entity
Saint Francis Sleep Allergy And Lung Institute
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis No dispute reported 06/30/2026 1235994109
Principal investigator 1 AstraZeneca Pharmaceuticals LP $22,787.67 01/08/2025 Non-covered Recipient Entity
SAINT FRANCIS SLEEP ALLERGY AND LUNG INSTITUTE
A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler MDI Relative to Budesonide and Formoterol Fumarate MDI and Symbicort pMDI in Adult and Adolescent Participants with Inadequately Controlled Asthma No dispute reported 06/30/2026 1185555822
Principal investigator 1 Genentech, Inc. $9,951.00 01/08/2025 Non-covered Recipient Entity
ST FRANCIS SLEEP ALLERGY AND LUNG INSTITUTE
Ph IIb of Astegolimab in COPD No dispute reported 06/30/2026 1211659071
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,464.30 01/06/2025 Non-covered Recipient Entity
St Francis Holdings LLC St Francis Medical Institute
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220799578
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
ST FRANCIS MEDCL INST
PDE4 Phase III trial in IPF patients No dispute reported 06/30/2026 1220622772
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
ST FRANCIS MEDCL INST
PDE4 Phase III trial in IPF patients No dispute reported 06/30/2026 1220622774
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
ST FRANCIS MEDCL INST
PDE4 Phase III trial in IPF patients No dispute reported 06/30/2026 1220622776
Principal investigator 1 Boehringer Ingelheim International GmbH $11.57 01/01/2025 Non-covered Recipient Entity
ST FRANCIS MEDCL INST
PDE4 Phase III trial in IPF patients No dispute reported 06/30/2026 1220622778
Principal investigator 1 Boehringer Ingelheim International GmbH $103.87 01/01/2025 Non-covered Recipient Entity
ST FRANCIS MEDCL INST
PDE4 Phase III trial in IPF patients No dispute reported 06/30/2026 1220622780
Principal investigator 1 Boehringer Ingelheim International GmbH $11.57 01/01/2025 Non-covered Recipient Entity
ST FRANCIS MEDCL INST
PDE4 Phase III trial in IPF patients No dispute reported 06/30/2026 1220622782
Principal investigator 1 Boehringer Ingelheim International GmbH $103.87 01/01/2025 Non-covered Recipient Entity
ST FRANCIS MEDCL INST
PDE4 Phase III trial in IPF patients No dispute reported 06/30/2026 1220622784
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $232.00 01/01/2025 Non-covered Recipient Entity
ST FRANCIS MEDCL INST
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) No dispute reported 06/30/2026 1220791631
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $34.00 01/01/2025 Non-covered Recipient Entity
ST FRANCIS MEDCL INST
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) No dispute reported 06/30/2026 1220791633